BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mirabilis Medica Restructures, Raises $10 Million Series A-1 Financing


6/18/2013 7:47:57 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

GSR Ventures is leading a $10 million restructuring round for Mirabilis Medica Inc. that will help the company drive a noninvasive treatment for uterine fibroids toward the market outside the U.S. GSR, a China-focused firm that seeks technologies that would appeal to the Chinese market, has been searching out opportunities in industries where U.S. investors have been pulling back, such as medical devices and clean technology, said Kevin Fong, a special adviser to GSR. Mirabilis's noninvasive treatment for uterine fibroids--noncancerous tumors that grow on the uterus wall--would be an alternative to more costly surgical procedures, Mr. Fong said. Products that reduce the cost of care are especially important in China because of the size of its population, he said. Mirabilis formed in 2004 and originally raised about $21 million from a group that included Arboretum Ventures, Charter Life Sciences, Dow Venture Capital, Split Rock Partners and vSpring Capital . But its original product required treatment times of about three to four hours, said Jens U. Quistgaard, its new chief executive.

Help employers find you! Check out all the jobs and post your resume.


Read at Dow Jones

Dow Jones
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES